JP2008511542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008511542A5 JP2008511542A5 JP2007518695A JP2007518695A JP2008511542A5 JP 2008511542 A5 JP2008511542 A5 JP 2008511542A5 JP 2007518695 A JP2007518695 A JP 2007518695A JP 2007518695 A JP2007518695 A JP 2007518695A JP 2008511542 A5 JP2008511542 A5 JP 2008511542A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- asthma
- hil
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000006673 asthma Diseases 0.000 claims description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 150000003431 steroids Chemical class 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 208000009657 Aspirin-Induced Asthma Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 208000024815 Granulomatous liver disease Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 208000004554 Leishmaniasis Diseases 0.000 claims description 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
- 201000009961 allergic asthma Diseases 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 208000029771 childhood onset asthma Diseases 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 231100000843 hepatic granuloma Toxicity 0.000 claims description 5
- 208000017694 hepatic granuloma Diseases 0.000 claims description 5
- 208000024696 nocturnal asthma Diseases 0.000 claims description 5
- 201000004409 schistosomiasis Diseases 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims 22
- 230000001225 therapeutic effect Effects 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 11
- 230000003993 interaction Effects 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 208000034189 Sclerosis Diseases 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 230000000750 progressive effect Effects 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000206602 Eukaryota Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000012657 Atopic disease Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0414799.7A GB0414799D0 (en) | 2004-07-01 | 2004-07-01 | Immunoglobulins |
| GB0414799.7 | 2004-07-01 | ||
| GB0423675.8 | 2004-10-25 | ||
| GB0423675A GB0423675D0 (en) | 2004-10-25 | 2004-10-25 | Immunoglobulins |
| PCT/GB2005/002581 WO2006003407A2 (en) | 2004-07-01 | 2005-06-30 | Chimeric and humanised monoclonal antibodies against inteleukin- 13 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008511542A JP2008511542A (ja) | 2008-04-17 |
| JP2008511542A5 true JP2008511542A5 (https=) | 2011-08-04 |
| JP5102616B2 JP5102616B2 (ja) | 2012-12-19 |
Family
ID=35521159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518695A Expired - Fee Related JP5102616B2 (ja) | 2004-07-01 | 2005-06-30 | 免疫グロブリン |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7807788B2 (https=) |
| EP (2) | EP1802658B1 (https=) |
| JP (1) | JP5102616B2 (https=) |
| KR (1) | KR20070034609A (https=) |
| AR (1) | AR049565A1 (https=) |
| AT (1) | ATE535545T1 (https=) |
| AU (1) | AU2005259025B2 (https=) |
| BR (1) | BRPI0512826A (https=) |
| CA (1) | CA2571799A1 (https=) |
| CY (1) | CY1112372T1 (https=) |
| DK (1) | DK1802658T3 (https=) |
| ES (2) | ES2456897T3 (https=) |
| HR (1) | HRP20120139T1 (https=) |
| IL (1) | IL180152A0 (https=) |
| MA (1) | MA28726B1 (https=) |
| MX (1) | MX2007000026A (https=) |
| NO (1) | NO20070189L (https=) |
| NZ (1) | NZ552063A (https=) |
| PE (1) | PE20060376A1 (https=) |
| PL (1) | PL1802658T3 (https=) |
| PT (1) | PT1802658E (https=) |
| RU (1) | RU2404192C2 (https=) |
| SG (1) | SG153878A1 (https=) |
| SI (1) | SI1802658T1 (https=) |
| TW (1) | TWI307630B (https=) |
| WO (1) | WO2006003407A2 (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| KR101073590B1 (ko) * | 2003-07-15 | 2011-10-14 | 메디뮨 리미티드 | Ｉｌ-13에 대한 인간 항체 분자 |
| SG10201404273QA (en) | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| JP2008520684A (ja) | 2004-11-17 | 2008-06-19 | アブジェニックス・インコーポレーテッド | Ｉｌ−１３に対する完全ヒトモノクローナル抗体 |
| US9072716B2 (en) | 2005-04-15 | 2015-07-07 | The United States of America, as represented by the Secretary Department of Health by Human Servies | Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells |
| AU2006296399B2 (en) | 2005-09-30 | 2011-01-20 | Medimmune Limited | Interleukin-13 antibody composition |
| RU2421464C2 (ru) | 2005-10-21 | 2011-06-20 | Новартис Аг | Человеческие антитела к il-13 и их терапевтическое применение |
| GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
| JP2009523460A (ja) * | 2006-01-24 | 2009-06-25 | ドマンティス リミテッド | Ｉｌ−４および／またはｉｌ−１３に結合するリガンド |
| CA2914170C (en) | 2006-09-08 | 2018-10-30 | Abbvie Bahamas Ltd. | Interleukin-13 binding proteins |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN101522716B (zh) * | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| DE102008053503B4 (de) * | 2008-10-28 | 2011-04-28 | Justus-Liebig-Universität Giessen | Immunologischer Test zum Nachweis von Autoantikörpern gegen testikuläre Antigene |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| EP2435481A1 (en) * | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Il-13 binding protein |
| ES2813398T3 (es) | 2009-10-20 | 2021-03-23 | Abbvie Inc | Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| TWI732259B (zh) | 2010-12-16 | 2021-07-01 | 美商建南德克公司 | 關於th2抑制作用之診斷及治療 |
| JP6306588B2 (ja) | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| ES2915378T3 (es) | 2013-09-13 | 2022-06-22 | Hoffmann La Roche | Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares |
| EP4331605A3 (en) | 2013-09-13 | 2024-05-22 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
| SG11201603127WA (en) | 2013-10-23 | 2016-05-30 | Genentech Inc | Methods of diagnosing and treating eosinophilic disorders |
| WO2015120171A1 (en) | 2014-02-07 | 2015-08-13 | Medimmune, Llc | Novel assay to detect human periostin |
| JP2017507939A (ja) | 2014-02-21 | 2017-03-23 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用 |
| KR102695088B1 (ko) | 2014-02-28 | 2024-08-16 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 |
| EP3129497B1 (en) | 2014-04-11 | 2021-09-08 | Novartis AG | Methods of selectively treating asthma using il-13 antagonists |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| EP3271723A1 (en) | 2015-03-16 | 2018-01-24 | F. Hoffmann-La Roche AG | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
| ITUB20155097A1 (it) * | 2015-11-05 | 2017-05-05 | Biouniversa Srl | Anticorpi umanizzati anti-BAG3 |
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| JP2019527535A (ja) * | 2016-05-18 | 2019-10-03 | 上海開拓者生物医薬有限公司Ｓｈａｎｇｈａｉ Ｐｈａｒｍａｅｘｐｌｏｒｅｒ Ｃｏ．， Ｌｔｄ． | Ｉｌ−１３抗体およびその製造方法と使用 |
| ES2994774T3 (en) | 2016-09-01 | 2025-01-31 | Regeneron Pharma | Methods for preventing or treating allergy by administering an il-4r antagonist |
| WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| KR102694419B1 (ko) | 2017-10-30 | 2024-08-09 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| AU2019218128A1 (en) | 2018-02-09 | 2020-09-17 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| BR112020020387A2 (pt) | 2018-05-13 | 2021-01-19 | Regeneron Pharmaceuticals, Inc. | Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| JP2022510377A (ja) * | 2018-12-03 | 2022-01-26 | デルマタ・セラピューティクス，エルエルシー | 状態の処置のための組成物 |
| MA55204A (fr) | 2019-03-06 | 2022-01-12 | Regeneron Pharma | Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| WO2021011614A1 (en) | 2019-07-16 | 2021-01-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| JP7836754B2 (ja) | 2019-08-05 | 2026-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法 |
| CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| AU2022425608A1 (en) | 2021-12-30 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
| EP4227321A1 (en) * | 2022-02-10 | 2023-08-16 | AVA Lifescience GmbH | Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll |
| TW202525846A (zh) | 2023-08-25 | 2025-07-01 | 美商普羅特歐拉吉克適美國公司 | 抗ｉｌ—１３多特異性抗體構築體及其用途 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US6051231A (en) * | 1988-09-01 | 2000-04-18 | Bayer Corporation | Antiviral methods and prepations |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| CA2114015C (en) | 1991-07-25 | 2002-12-10 | Roland A. Newman | Recombinant antibodies for human therapy |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| HU225869B1 (en) | 1992-04-02 | 2007-11-28 | Smithkline Beecham Corp | Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them |
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| EP0957087B1 (en) | 1994-06-15 | 2002-12-04 | The Wellcome Foundation Limited | Intermediates useful in the preparation of enzyme inhibitors |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| JP2002506856A (ja) | 1998-03-14 | 2002-03-05 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | フタラジノンｐｄｅｉｉｉ／ｉｖ阻害剤 |
| GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| WO1999055369A1 (en) | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| WO2000044407A2 (en) * | 1999-02-01 | 2000-08-03 | Amgen Canada | Materials and methods to inhibit hodgkin and reed sternberg cell growth |
| HK1043788A1 (zh) | 1999-05-04 | 2002-09-27 | American Home Products Corporation | 四環黃體酮受體調節劑化合物及方法 |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US6263209B1 (en) | 1999-07-28 | 2001-07-17 | Motorola, Inc. | Method and apparatus in a wireless communication system for creating a learning function |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| IL155093A0 (en) | 2000-09-29 | 2003-10-31 | Glaxo Group Ltd | Morpholin-acetamide derivatives for the treatment on inflammatory diseases |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| GB0105360D0 (en) | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
| EP1366025B1 (en) | 2001-03-08 | 2007-06-27 | Glaxo Group Limited | Agonists of beta-adrenoreceptors |
| JP4143413B2 (ja) | 2001-03-22 | 2008-09-03 | グラクソ グループ リミテッド | β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体 |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| CN1555548A (zh) * | 2001-09-20 | 2004-12-15 | 先锋株式会社 | 发光元件驱动电路 |
| US20030235555A1 (en) * | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| CA2472746A1 (en) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| JP4745609B2 (ja) | 2002-01-22 | 2011-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| WO2003080675A2 (en) * | 2002-03-22 | 2003-10-02 | Amrad Operations Pty Ltd | MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1) |
| UA80120C2 (en) | 2002-03-26 | 2007-08-27 | Boehringer Ingelheim Pharma | Glucocorticoid mimetics, pharmaceutical composition based thereon |
| CA2477764A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| DE60335869D1 (de) | 2002-04-11 | 2011-03-10 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
| AU2003243189B2 (en) | 2002-05-01 | 2008-01-24 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat HIV infection and AIDS |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| SI1521733T1 (sl) | 2002-07-08 | 2014-10-30 | Pfizer Products Inc. | Modulatorji glukokortikoidnega receptorja |
| ES2337679T3 (es) | 2002-07-18 | 2010-04-28 | Bristol-Myers Squibb Company | Composiciones y procedimientos que implican el sitio ii de los receptores nucleares de hormonas. |
| WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| US20040219142A1 (en) * | 2002-07-19 | 2004-11-04 | Abbott Laboratories S.A. | Treatment of skin and nail disorders using TNFalpha inhibitors |
| CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| CN100387598C (zh) | 2002-09-16 | 2008-05-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
| EP1542996A4 (en) | 2002-09-20 | 2009-11-18 | Merck & Co Inc | OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| US7790405B2 (en) * | 2004-04-26 | 2010-09-07 | Centocor, Inc. | Solution phase biopanning method using engineered decoy proteins |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
-
2005
- 2005-06-29 TW TW094121993A patent/TWI307630B/zh not_active IP Right Cessation
- 2005-06-30 AR ARP050102731A patent/AR049565A1/es unknown
- 2005-06-30 MX MX2007000026A patent/MX2007000026A/es active IP Right Grant
- 2005-06-30 EP EP05757024A patent/EP1802658B1/en not_active Expired - Lifetime
- 2005-06-30 HR HR20120139T patent/HRP20120139T1/hr unknown
- 2005-06-30 WO PCT/GB2005/002581 patent/WO2006003407A2/en not_active Ceased
- 2005-06-30 AU AU2005259025A patent/AU2005259025B2/en not_active Ceased
- 2005-06-30 RU RU2007103826/10A patent/RU2404192C2/ru not_active IP Right Cessation
- 2005-06-30 ES ES11181891.0T patent/ES2456897T3/es not_active Expired - Lifetime
- 2005-06-30 CA CA002571799A patent/CA2571799A1/en not_active Abandoned
- 2005-06-30 PL PL05757024T patent/PL1802658T3/pl unknown
- 2005-06-30 US US11/570,736 patent/US7807788B2/en not_active Expired - Fee Related
- 2005-06-30 PE PE2005000762A patent/PE20060376A1/es not_active Application Discontinuation
- 2005-06-30 NZ NZ552063A patent/NZ552063A/en not_active IP Right Cessation
- 2005-06-30 KR KR1020077002166A patent/KR20070034609A/ko not_active Abandoned
- 2005-06-30 ES ES05757024T patent/ES2378173T3/es not_active Expired - Lifetime
- 2005-06-30 JP JP2007518695A patent/JP5102616B2/ja not_active Expired - Fee Related
- 2005-06-30 SG SG200904563-4A patent/SG153878A1/en unknown
- 2005-06-30 BR BRPI0512826-9A patent/BRPI0512826A/pt not_active IP Right Cessation
- 2005-06-30 AT AT05757024T patent/ATE535545T1/de active
- 2005-06-30 DK DK05757024.4T patent/DK1802658T3/da active
- 2005-06-30 SI SI200531473T patent/SI1802658T1/sl unknown
- 2005-06-30 EP EP11181891.0A patent/EP2436697B1/en not_active Revoked
- 2005-06-30 PT PT05757024T patent/PT1802658E/pt unknown
-
2006
- 2006-12-18 IL IL180152A patent/IL180152A0/en unknown
- 2006-12-29 MA MA29577A patent/MA28726B1/fr unknown
-
2007
- 2007-01-11 NO NO20070189A patent/NO20070189L/no not_active Application Discontinuation
-
2010
- 2010-08-24 US US12/862,235 patent/US20110243928A1/en not_active Abandoned
-
2012
- 2012-02-21 CY CY20121100172T patent/CY1112372T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008511542A5 (https=) | ||
| JP2009523154A5 (https=) | ||
| CN104774266B (zh) | 白介素-13结合蛋白 | |
| CN113527485B (zh) | 抗人白细胞介素-4受体α抗体及其制备方法和应用 | |
| HRP20120139T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv interleukina 13 | |
| JP2020517249A5 (https=) | ||
| JP2010520290A5 (https=) | ||
| JP2020503260A5 (https=) | ||
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| BRPI1009576B1 (pt) | anticorpo antagonístico que se liga a il-13 humana e uso deste, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de anticorpo, composição famacêutica, e uso de fragmento fab ou fab` de anticorpo anti-il 13. | |
| JP2013502932A5 (https=) | ||
| JP2021520825A5 (https=) | ||
| RU2013110874A (ru) | Антитела против il-18r1 и их применения | |
| JP2011516041A5 (https=) | ||
| JP2017507945A5 (https=) | ||
| JP2018522540A5 (https=) | ||
| JP2021525059A5 (https=) | ||
| EP4031569B1 (en) | Anti-stem cell factor antibodies and methods of use thereof | |
| JP2020504135A5 (https=) | ||
| JP2024542777A (ja) | 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン | |
| ES3057414T3 (en) | Interleukin 5 binding protein dosage regimen | |
| CN119183384A (zh) | 针对警报素的双特异性结合蛋白及其用途 | |
| JPWO2021007533A5 (https=) | ||
| JPWO2020243448A5 (https=) | ||
| JPWO2021026508A5 (https=) |